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Abstract
Background: Metastatic urothelial cancer (UC) is the eighth most common cause of cancer death in the UK.
Standard first-line treatment, for most patients, is cytotoxic chemotherapy. Although UC is initially sensitive to
chemotherapy, relapse is almost inevitable and outcomes are poor; median overall survival is 8 months. Therefore,
there is an urgent need for novel therapies to improve outcomes for this patient group.
Methods: ATLANTIS is a randomised phase II umbrella-design screening trial of maintenance therapy in biomarker-
defined subgroups of patients with advanced UC. The primary end point is progression-free survival, and the study
involves over 30 UK cancer centres.
Discussion: ATLANTIS is the first study in the UK to employ a precision-medicine approach to patients with UC for
maintenance treatment. Agents with a positive efficacy signal will proceed to randomised phase III trials to confirm
the activity of novel, biologically stratified therapies in UC.
Registration: ATLANTIS trial EudraCT number 2015–003249-25. ISRCTN25859465.
Keywords: Urothelial cancer, Precision medicine, Biomarker
Background
Urothelial cancer (UC) is the eighth most common cause
of cancer-related death in the UK. Around 5300 patients
died from UC in the UK in 2016 (Cancer Research UK,
2017). Cytotoxic platinum-based doublet chemotherapy is
routinely used for metastatic or locally advanced disease
in the first-line setting [1, 2]. Although the majority of pa-
tients derive benefit, relapse is almost inevitable and
occurs an average of 4months after completion. Once re-
lapse has occurred, survival and quality of life are often
poor; median progression-free survival (PFS) and overall
survival (OS) are short: 2 and 8months respectively [3]. In
recent years, immune checkpoint inhibitors, which can
benefit around 20% of patients with durable responses and
proven survival advantage, have found a role in second-
line treatment after failure of platinum-based chemother-
apy [4, 5]. Their role in first-line treatment is currently
limited to patients who have high programmed death-
ligand 1 (PD-L1) expression and who are not suitable for
platinum-based chemotherapy [6, 7]. However, there are
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still a majority of patients with advanced UC who do not
derive significant benefit from immune checkpoint inhibi-
tors and whose subsequent treatment options are very
limited. Second-line chemotherapy may be used, but re-
sponse rates are low and benefit compared with best sup-
portive care is uncertain, although recent data suggest that
the combination of docetaxel and the vascular endothelial
growth factor (VEGF) targeted antibody ramucirumab
may provide modest benefits in selected patients in the
second-line setting [8].
Therefore, there is a clear need for new effective treat-
ments for patients with advanced UC. The molecular het-
erogeneity of UC suggests that patients may be well served
by a precision-medicine approach. Testing new drugs in
combination with first-line chemotherapy is often challen-
ging because of toxicity of combinations in this patient
group [9]. Studies in the second-line setting have historic-
ally been limited by the high symptom burden and poor
prognosis for patients. Therefore, maintaining clinical bene-
fit after first-line chemotherapy may be an attractive way to
improve outcomes for patients with advanced UC.
Maintenance therapy after first-line chemotherapy is an
opportunity for novel drug development in advanced UC.
This was demonstrated in the UK NCRI LAMB trial,
which completed accrual in 2013 after having screened
520 patients and randomly assigned 221 patients with epi-
dermal growth factor–expressing urothelial tumours from
over 40 UK sites between lapatinib and placebo (Clinical-
Trials.gov Identifier: NCT00949455). In that trial, lapati-
nib did not prolong survival or PFS in any of the defined
subgroups, confirming observation alone as the standard
of care in this patient group [10]. The study did reinforce
the proof of concept that such a trial would be acceptable
to patients and could be successfully delivered in the UK.
Methods and study design
ATLANTIS is a multi-centre randomised phase II
signal-searching umbrella-design screening trial of tar-
geted novel agents in biomarker-defined subgroups
(Fig. 1). Multiple novel agents will be used in parallel
and patients will be entered into ATLANTIS subgroup
studies dependent on tumour biomarker profile. The
Fig. 1 Study design for patients in ATLANTIS trial. Abbreviations: MET MET proto-oncogene, PFS progression-free survival, VEGF vascular endothelial
growth factor
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control arm for each comparison will be matched placebo,
and comparison will be double-blind where possible.
Trial population
The target population in ATLANTIS consists of patients
with metastatic or locally advanced UC (T4b and/or N1–3
and/or M1) who are not being considered for radical ther-
apy. Patients must have achieved an objective response or
stable disease, according to local radiology review, after 4–
8 cycles of first-line chemotherapy. Patients must be able
to start maintenance treatment within the study at least 3
but no more than 10 weeks after completion of their first
line of chemotherapy for metastatic or locally advanced
disease. Biomarker analysis of archival tissue to determine
ATLANTIS biomarker-defined subgroups can occur any
time after the diagnosis of UC, after appropriate consent
has been given.
Study objectives and end points
The principal research question is whether molecularly
targeted maintenance therapy after chemotherapy can
delay the time to progression in molecularly selected pa-
tients with advanced UC. ATLANTIS will thereby estab-
lish initial evidence of activity for the novel drug/
biomarker combinations used in order to justify further
phase III validation. A number of drugs will be tested,
each compared with placebo or (where this is not feas-
ible) observation alone. Treatment will be allocated on
the basis of molecularly defined subgroups of patients
(where laboratory/clinical evidence to support such en-
richment is clear) or in a manner that allows exploration
of, or provides initial evidence for, predictive biomarkers.
Of note, it is anticipated that in most cases the bio-
marker for a particular arm of the trial will itself be ex-
perimental and not yet prospectively validated.
The primary end point is PFS. This has been chosen
as it is largely objective and the majority of patients with
UC display progression in accordance with RECIST 1.1
criteria. PFS is also clinically meaningful as the progres-
sion after first-line chemotherapy represents the transi-
tion to the lethal stage of the disease and often the
requirement for further systemic therapy.
The secondary end points in ATLANTIS are OS, re-
sponse rate, maximum percentage decrease in measur-
able disease, safety and tolerability. Exploratory end
points are PFS in biomarker-defined subgroups other
than those used for selection. Exploratory research hy-
potheses are embedded in the primary purpose of the
trial. As such, all patients must provide adequate tissue
for biomarker analysis prior to participation in the trial.
This tissue collection will provide a bio-resource for fu-
ture research relating to UC. The trial also provides a
generic umbrella-design framework allowing new drugs
to be introduced by amendment in the future. The
SPIRIT (Standard Protocol Items: Recommendations for
Interventional Trials) figure for ATLANTIS trial is
shown in Fig. 2.
Current biomarker-defined arms in ATLANTIS
The design of ATLANTIS allows for the addition of fur-
ther biomarker-defined subgroups throughout the life-
time of the trial. At initiation, ATLANTIS was exploring
a single drug (cabozantinib) but other comparisons, each
with associated Investigational Medicinal Product (IMP),
have been added since the trial began:
Cabozantinib
A wide body of pre-clinical evidence supports the rele-
vance of hepatocyte growth factor, the ligand for MET,
and VEGF as anti-cancer targets in patients with UC
[11]. Cell-line data show that MET is associated with
tumour proliferation and growth [12]. VEGF has also
been demonstrated to be over-expressed in UC cell lines
and associated with tumour proliferation [13]. Therefore,
the combination of VEGF and MET inhibition is an at-
tractive field in patients with UC. Cabozantinib is a
multi-kinase inhibitor including MET and VEGF. It has
been demonstrated to have significant activity and is li-
censed in Europe to treat medullary thyroid and renal
cancers [14]. It has shown early signs of activity in an
ongoing phase II trial in patients with advanced UC [15].
There is currently a lack of data on the expression of
MET or VEGF as a biomarker for cabozantinib activity.
For this reason, all patients in ATLANTIS and other on-
going studies have not selected patients on the basis of
MET expression. Therefore, patients in this study will
potentially be eligible for the cabozantinib/placebo arm
if their tumour does not over-express any current AT-
LANTIS target biomarker or they are not deemed suit-
able to enter a biomarker-defined arm of the study.
Rucaparib
There is emerging evidence of a subgroup of patients with
UC exhibiting a DNA repair deficiency phenotype result-
ing in defects in a variety of genes, including BRCA1/2,
BAP1, PALB2, FANCD2 and ERCC2 [16, 17]. These DNA
repair gene defects predict for benefit following cisplatin-
based chemotherapy in UC, implying that a switch to
maintenance therapy strategy for poly (ADP-ribose) poly-
merase (PARP) inhibition after prior chemotherapy may
allow for enrichment of a ‘BRCA-like’ subgroup. PARP in-
hibition has demonstrated activity against multiple UC cell
lines and xenografts. Evidence supports the development
of PARP inhibitors in patients with either germline or
somatic BRCA mutations and, in addition, a wider se-
lected group with evidence of homologous recombination
deficiency (HRD)-associated tumours [18]. PARP inhibi-
tors have demonstrated compelling evidence of efficacy in
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patients with relapsed high-grade serous ovarian cancer
demonstrating germline or somatic BRCA mutation [19].
The concept of synthetic lethality was confirmed in proof-
of-concept studies in patients with BRCA-associated tu-
mours where data suggest that BRCA mutation is signifi-
cant but not required.
Fig. 2 Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) figure: Schedule of Assessments for ATLANTIS trial. (1) Patients
should have signed and dated informed consent forms for pre-screening. (2) Each patient must have signed and dated both informed consent
forms for pre-screening biomarker testing and full trial screening before engaging in any trial-related procedures. All screening evaluations must
be completed before the patient is randomly assigned to receive trial drug or placebo. (3) Patient characteristics will be collected at pre-
screening. These data should be collected only if they are available from data collection during the previous 6 weeks as part of standard care. No
additional blood tests should be performed during pre-screening purely for the trial. (4) Tumour samples and all other translational samples
should be sent to the attention of Charlotte Ackerman for centralised pre-screening or confirmation. If there is any tissue left from biomarker
testing, it will be stored in the Orchid Tissue Bank for future translational research. Individual samples will be returned at the end of the trial on
request. Samples will be processed in accordance with the ATLANTIS lab manual. (5) Weight, height, pulse and blood pressure. (6) Human
chorionic gonadotropin (HCG) results must be obtained and reviewed before the first dose of Investigational Medicinal Product (IMP) is
administered for women of child-bearing potential. (7) Haematology, including full blood count with white blood cell count, absolute neutrophil
count, platelet count and haemoglobin. Biochemistry, including sodium, potassium, aspartate aminotransferase/alanine aminotransferase (AST/
ALT), alkaline phosphatise, lactate dehydrogenase, bilirubin, creatinine, protein and albumin. (8) All patients should have abdominal and pelvic
computed tomography (CT) or magnetic resonance imaging (MRI) plus either chest x-ray (postero-anterior and lateral views) or chest CT scan. If
known or thoracic metastases are seen on chest x-ray, patients must have a thoracic CT scan. Patients should have baseline scanning every 12
weeks until week 49; following this, scans should be carried out at the discretion of the individual clinician. (9) Patients who come off the trial
should have tumour assessments within 4 weeks of coming off trial drug/placebo, irrespective of whether the patient is still being followed up
for progression. (10) Patients who come off the trial should have tumour measurements where they have not been completed within the past 4
weeks. This includes abdominal and pelvic CT or MRI plus either chest x-ray (postero-anterior and lateral views) or chest CT scan. If known or
thoracic metastases are seen on chest x-ray, patients must have a thoracic CT scan. Patients who stop treatment for whatever reason before
progressive disease is documented will continue to have scans at 12-weekly intervals as previously. (11) Follow-up visits after progression will
continue at the investigators’ discretion until death. Future treatment and cause of death must be recorded on the case report form. (12)
Frequency of treatment visits will vary within the different treatment arms; please see individual IMP drug appendices for this information.
Abbreviations: ECG electrocardiogram, GFR glomerular filtration rate, WHO World Health Organization
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These data imply that BRCA mutation or HRD-
associated UC patient subgroups (or both) would be
suitable for investigation of a PARP inhibitor. Rucaparib
is an orally bioavailable small-molecule inhibitor of
PARP1, PARP2 and PARP3. Non-clinical evaluation of
rucaparib has demonstrated potent inhibition of PARP
enzymes and sensitivity to BRCA1/2 homozygous mu-
tant cell lines. Patients in ATLANTIS whose tumour is
positive for a composite ‘HRD biomarker’ of alterations
to a list of relevant DNA repair genes or high percentage
genomic loss of heterozygosity (LOH) at pre-screening
(or both) will potentially be eligible to receive either
rucaparib or placebo in a double-blind fashion. LOH is a
form of genomic alteration associated with HRD and is
characterised by the loss of one copy of a gene or
chromosomal region.
Enzalutamide
Previous in vivo and in vitro data have demonstrated
that the androgen receptor (AR) is a potential anti-
cancer target receptor in patients with UC [20, 21]. Un-
published data from tissue microarray in patients tested
within the LAMB study demonstrated that 30% of UC
tumours over-express the AR. This was also associated
with poorer prognosis, raising potential clinical benefit
of targeted agents against AR. Enzalutamide is a potent
AR antagonist which, unlike earlier generations of anti-
androgen therapies, has no known agonistic effect on
AR and is known to be active in men with prostate can-
cer who have previously failed conventional androgen
deprivation therapy. The drug is well tolerated even with
prolonged administration [22]. Patients in ATLANTIS
whose tumour is found to over-express the AR on im-
munohistochemical analysis will potentially be eligible to
receive either enzalutamide or placebo in a double-blind
fashion.
Trial analysis plan
The design of each ATLANTIS subgroup is based on a
randomised phase II screening design to detect a certain
level of improvement in PFS with the novel drug com-
pared with matched placebo with 90% power at the 20%
one-sided level of statistical significance or equivalently
with 80% power at the 10% level of statistical signifi-
cance. At the end of each subgroup analysis, if the ob-
served PFS difference in favour of the novel agent is
statistically significant, this may be a signal that a subse-
quent phase III trial is warranted. Within each subgroup
of ATLANTIS, randomisation (1:1) will be stratified via
minimisation factors according to the following: cisplatin
versus non-cisplatin primary chemotherapy, Eastern Co-
operative Oncology Group (ECOG) score, best response
to first-line chemotherapy, progression during the final
three months of chemotherapy, presence of visceral
metastases, presence of measurable disease at trial entry
and investigational site.
The data analysis will be on an intention-to-treat basis
within each trial subgroup. PFS will be compared be-
tween the novel agent and placebo in each study sub-
group within the context of a Cox model incorporating
the baseline minimisation factors, based on a rando-
mised phase II screening design to detect improvement
in PFS with the novel drug compared with placebo/ob-
servation. The P value for the observed hazard ratio will
be determined from the Cox model in each subgroup. If
the observed PFS difference in favour of the novel agent
is statistically significant at the 10% one-sided level, this
will be deemed a clear signal that a subsequent phase III
trial is warranted. A result significant at the 20% one-
sided level would require further evidence in terms of
improvement, such as reduction in size of measurable
disease. A Mann–Whitney U test will be used for this
comparison. This decision-making process follows a
three-outcome-type design. The OS and PFS will be il-
lustrated by using Kaplan–Meier plots. Response rates
will be compared within subgroups in the context of a
logistic model incorporating minimisation factors. The
worst toxicity grades experienced during chemotherapy
will be compared by using the Mann–Whitney U test.
The study data will be reviewed roughly annually by
an independent data monitoring committee (IDMC). In
each ATLANTIS subgroup, there is a non-binding test
for futility after half the PFS events have occurred based
on a Lan–DeMets monitoring boundary with an
O’Brien–Fleming stopping rule. The IDMC will also re-
view toxicity, treatment delivery and compliance data.
Recommendations will take into account all available
data as well as formal futility comparison for PFS within
each trial subgroup.
Sample size
Patients within the cabozantinib subgroup will be ran-
domly assigned to cabozantinib/placebo in a 1:1 ratio.
The median PFS on the placebo arm is estimated to be
6 months. The comparison between arms is designed to
detect an improvement in median PFS of 9 months with
cabozantinib, which corresponds to a hazard ratio of
0.67. This is appropriate for a new agent within an
untargeted population and requires 114 PFS events, so
recruitment to this subgroup will incorporate 140 pa-
tients over about 24 months. This target provides more
than 90% power (10% one-sided) to detect between the
study arms a difference in reduction of measurable dis-
ease corresponding to a standardised effect size of 0.5.
Patients allocated to the rucaparib subgroup will be ran-
domly assigned to rucaparib/placebo in a 1:1 ratio. A
hazard ratio for this subgroup of 0.5 is targeted on the
basis of the striking effect seen with PARP inhibitors in
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a similar setting with ovarian cancer using HRD bio-
marker for patient selection. This requires 39 PFS
events, which can be obtained by recruiting 48 patients.
This recruitment number also provides more than 80%
power (10% one-sided) to detect a difference of reduc-
tion in size of measurable disease corresponding to stan-
dardised effect size of 0.7.
Patients allocated to the enzalutamide subgroup will
be randomly assigned to enzalutamide/placebo in a 1:1
ratio. The median PFS on the placebo arm is estimated
to be 4 months. The comparison between arms is de-
signed to detect an improvement in median PFS of 6.7
months with enzalutamide, corresponding to a hazard
ratio of 0.6. This size of difference is appropriate in a
targeted agent in the target population. This requires 72
PFS events, so recruitment to this subgroup will incorp-
orate 80 patients. This number also provides 90% power
(10% one-sided) to detect between the arms a difference
in the reduction in size of measurable disease corre-
sponding to standardised effect size of 0.65.
Discussion
Recent studies of second-line therapy, particularly im-
mune checkpoint inhibitors, in patients with UC have
demonstrated a clinical benefit for a small proportion of
patients. The emerging treatment landscape of UC is
also increasingly incorporating these therapies in first-
line clinical trials. However, there remains a need to im-
prove outcomes for patients with this challenging dis-
ease. ATLANTIS offers a novel approach to previous
studies in this arena by offering biomarker-defined selec-
tion of maintenance therapy after chemotherapy in pa-
tients with UC. The primary research question of this
signal-searching multi-arm phase II study is whether tar-
geted maintenance therapy after chemotherapy can delay
the time to progression in molecularly selected patients
with UC. This would establish clinically relevant evidence
of activity in molecularly defined subgroups for the novel
drug used. The study design will investigate cabozantinib,
enzalutamide and rucaparib in this setting but also pro-
vide a generic framework that will allow new treatments
to be introduced into the study in the future with pro-
spective stratification based on a molecular target.
At present, there are no targeted therapies with proven
activity in UC. Pre-clinical data suggest that there are a
number of eligible targets, but the number of rando-
mised trials performed to test these hypotheses has been
small. The reasons behind this remain unclear, but low
levels of clinical activity in unselected patients with UC
in non-randomised phase II trials do not support pro-
gression to phase III trials. Another explanation is that
the combination of targeted therapy and standard
chemotherapy is poorly tolerated in this patient popula-
tion. ATLANTIS will be a leading global study in the
development of personalised targeted therapy for pa-
tients with UC.
Such a positive randomised phase II study would be a
significant breakthrough in UC and may lead to rando-
mised phase III trials in both the metastatic and adju-
vant setting. If a cohort of ATLANTIS is positive, it
would be anticipated to lead to a randomised phase III
study of maintenance therapy in the appropriately se-
lected UC population. There is also an unmet need for
adjuvant therapy in patients with high-risk muscle inva-
sive bladder cancer, and a positive signal from ATLAN-
TIS would also support a randomised phase III trial in
this patient group with appropriate molecular selection.
Patients in ATLANTIS are asked to consent to the
collection of surplus tissue for translational research.
Translational research hypotheses are embedded in the
primary purpose of this trial, the aim of which is to dem-
onstrate efficacy of predictive and appropriate drug in-
terventions in UC. As such, all patients must provide
adequate tissue for biomarker expression prior to trial
participation. This will also provide a bio-resource for
future research in UC.
The ATLANTIS trial reflects an exciting innovation in
front-line precision cancer medicine for patients with
advanced UC. The study design, with a biomarker-
negative arm, allows all patients who enter pre-screening
to potentially be able to take part. The adaptive design
also allows maximal opportunity to detect an efficacy
signal and rapid inclusion of new hypotheses. The en-
grained translational research components have the po-
tential to resolve some of the unanswered questions and
push new frontiers in the management of this challen-
ging disease.
Trial status
At the time of publication, ATLANTIS was open to re-
cruitment across 32 UK cancer centres. Trial recruitment
began in November 2016, and the estimated first sub-
group recruitment end date is December 2020. The
current ATLANTIS protocol is version 2.4 (21 June 2019).
Supplementary information
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